What baseline laboratory tests and assessments are needed before starting bevacizumab therapy?

Baseline Blood Pressure Assessment is the Essential Pretest Before Starting Bevacizumab

Measure clinic blood pressure before initiating bevacizumab; start therapy only if BP is <160/100 mmHg. 1

Required Baseline Assessments

Blood Pressure Monitoring (Critical)

• Clinic BP measurement is mandatory before starting bevacizumab 1
• If clinic BP is <160/100 mmHg: Start bevacizumab immediately without additional antihypertensive treatment 1
• If clinic BP is ≥160/100 mmHg: Do NOT start bevacizumab 1
  • Arrange ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) to confirm sustained hypertension
  • HBPM should be performed over at least 4 consecutive days (ignore day 1 measurements) 1
  • If ABPM/HBPM shows ≥150/95 mmHg: Delay bevacizumab and initiate amlodipine 5 mg daily in treatment-naive patients 1
  • Reassess after at least 2 weeks; start bevacizumab only when BP falls below threshold 1

Proteinuria Screening (Important)

Monitor for proteinuria using dipstick urinalysis before starting therapy 2. The FDA label emphasizes that:

• Proteinuria occurs in up to 20% of patients (median onset 5.6 months) 2
• Grade 3-4 proteinuria (urine dipstick 4+ or >3.5 grams/24 hours) occurs in 0.7-7% of patients 2
• Patients with 2+ or greater dipstick reading require 24-hour urine collection for quantification 2
• Withhold bevacizumab if proteinuria ≥2 grams per 24 hours; resume when <2 grams per 24 hours 2
• Discontinue permanently if nephrotic syndrome develops 2

Cardiovascular Risk Assessment

For patients with significant pre-existing cardiovascular disease, optimize treatment in consultation with their general practitioner and cardiologist before initiating bevacizumab 1. This is particularly important given bevacizumab's association with:

• Hypertension and hypertensive crises 2
• Arterial thromboembolic events (including MI, stroke, angina) 2
• Venous thromboembolic events 2

Wound Healing Considerations

Do NOT initiate bevacizumab within 28 days of major surgery 2. Bevacizumab impairs wound healing, and therapy should be withheld until surgical wounds are fully healed 2.

Laboratory Tests NOT Specifically Required

While the provided evidence focuses heavily on blood pressure and proteinuria monitoring, standard baseline laboratory assessments (CBC, comprehensive metabolic panel, liver function tests) are part of routine oncology practice but are not specifically mandated by bevacizumab guidelines. The research evidence suggests that certain baseline markers may have prognostic value:

• Neutrophil count (baseline <6000/mm³ may predict better bevacizumab response) 3
• Inflammatory markers (CRP, LDH, albumin, NLR) may have prognostic significance 4
• However, these are investigational biomarkers, not established pretests for treatment eligibility

Common Pitfalls to Avoid

1. Do not rely solely on clinic BP readings when there is discrepancy with ABPM/HBPM (>20/10 mmHg difference); clinical decisions should primarily use ABPM/HBPM values as they are more reliable 1

2. Do not use UPCR (Urine Protein/Creatinine Ratio) as substitute for 24-hour urine collection - postmarketing data showed poor correlation (Pearson Correlation 0.39) 2

3. Do not delay cancer treatment unnecessarily - the short-term absolute risk of moderately elevated BP is low; BP <160/100 mmHg should not be a barrier to starting bevacizumab 1

4. Ensure coordination with primary care for ongoing BP management, as oncology units should initiate hypertension management but primary care teams are best positioned for long-term monitoring 1